AUS
NZ
UK
CA
USA
IND
BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) is on the brink of a significant milestone as it prepares to commence mass production and initiate sales of its revolutionary EZ-G device. This pivotal development underscores the culmination of extensive research and innovation aimed at addressing crucial women's health issues through advanced technology.
At the heart of this achievement is Yftah Ben Yaackov, the Chief Executive Officer of BYND Cannasoft, whose vision and leadership have been instrumental in bringing the EZ-G device to fruition. Recognizing his pivotal role, the governance, nominating, and compensation committee recently took decisive action. on June 11, 2024, they resolved to grant Mr. Ben Yaackov 1,038,525 restricted share units (rsus) as a form of compensation for his dedicated service over the past four years.
Throughout his tenure, Mr. Ben Yaackov has been a driving force behind BYND Cannasoft's growth, particularly championing the development of the EZ-G device. His strategic insights and relentless efforts have significantly contributed to the company's expansion, particularly in the competitive landscape of Israel's tech sector.
The decision to award RSUs to Mr. Ben Yaackov reflects not only his pivotal role but also the Committee's recognition of his substantial contributions, which have been integral to the company's success. The RSUs, granted based on a thorough independent appraisal and market benchmarking, vest immediately but are subject to a 12-month lockup period, underscoring the long-term alignment of Mr. Ben Yaackov's interests with those of BYND Cannasoft's shareholders.
BYND Cannasoft Enterprises Inc., headquartered in Israel, is renowned for its innovative software solutions, notably the proprietary "Benefit CRM" software that empowers small and medium-sized businesses to optimize their operations across various functions such as sales, marketing, and personnel management.
Central to BYND Cannasoft's portfolio is the patent-pending EZ-G device, a groundbreaking therapeutic device designed to administer controlled doses of CBD oil, hemp seed oil, and other natural oils to the soft tissues of the female reproductive system. This pioneering technology aims to address a diverse range of women's health issues, offering potential therapeutic benefits through its unique application of software-driven regulation.
The path to commercialization for the EZ-G device hinges on securing regulatory approvals, a critical next step as BYND Cannasoft prepares to introduce this innovative technology to the market. The company's commitment to advancing women's health through cutting-edge solutions underscores its dedication to innovation and improving quality of life.
